Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance

• Published in: British journal of clinical pharmacology Vol. 53; no. 3; pp. 224 - 231
• Main Authors: Brazell, C., Freeman, A., Mosteller, M.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science, Ltd 01-03-2002; Blackwell Science; Blackwell Science Inc
• Subjects: adverse drug reactions; Biological and medical sciences; clinical trials; Cost-Benefit Analysis; Drug Design; General pharmacology; Humans; marketing surveillance; Medical sciences; medicine response test; Patient Participation; pharmacogenetics; Pharmacogenetics - economics; Pharmacogenetics - methods; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Review Series; single nucleotide polymorphism; Pharmacogenetics; Toxicity; Genetics; Clinical trial; Candidate gene; Drug interaction; Single nucleotide polymorphism; Biological monitoring; Cost efficiency analysis
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1046/j.0306-5251.2001.01556.x

Genetics provides significant opportunities to maximize the safety and efficacy of medicines. Over the next 3–5 years, it may be possible to develop tools that use selective information from patients' DNA to enable healthcare professionals to predict more accurately those patients at risk of serious adverse events to some medicines currently available. This is likely to be followed, over the next 5–10 years, by the application of the technology to predict more accurately if individual patients will obtain a therapeutic benefit from a particular medicine. The ability to accurately predict patient response will inevitably change the way medicines are developed, evaluated, and prescribed. Advances in single nucleotide polymorphism (SNP) map technology are likely to drive this innovation. Abbreviated SNP profiles will provide the means to define medicine response tests, thereby allowing clinicians to select the medicine to which the patient is likely to gain the greatest benefit and least risk. This will help to maximize efficacy and reduce the incidence of drug‐related adverse events. It may be possible to identify SNP profiles during larger Phase II clinical trials which predict efficacy, and use these to form the basis of Phase III entry criteria. As a result, Phase III trials may be streamlined for many medicines making them smaller, more efficient, and more focused. In addition it may be possible to incorporate pharmacogenetics into postmarketing surveillance strategies to provide a means to identify SNPs which predict uncommon serious adverse drug reactions, and so refine the initial medicine response test. The ability to develop drugs with a predictable response will allow clinicians to provide targeted treatment for patients, with greater confidence of safety and efficacy. Patients therefore will receive more efficacious, timely, and well‐tolerated medicines. The challenge for those involved in drug development is to model and evaluate the application of pharmacogenetics so that steps can be taken to realize this potential.